News
AKTX
1.180
-19.73%
-0.290
Akari Therapeutics regains full Nasdaq comliance
TipRanks · 2d ago
Akari Therapeutics Regains Full Nasdaq Compliance, Shareholders Equity Deficiency Has Been Cured
Benzinga · 2d ago
AKARI THERAPEUTICS PLC - NASDAQ HEARING FOR AKARI THERAPEUTICS ON NOVEMBER 21 CANCELLED
Reuters · 2d ago
Weekly Report: what happened at AKTX last week (1111-1115)?
Weekly Report · 3d ago
Akari Therapeutics Completes Merger with Peak Bio and Secures $3.2 Million in PIPE Financing
Barchart · 6d ago
Akari Therapeutics Advances Post-Merger with Strategic Moves
TipRanks · 11/14 21:54
AKARI THERAPEUTICS ANNOUNCES SUCCESSFUL COMPLETION OF MERGER OF AKARI THERAPEUTICS AND PEAK BIO
Reuters · 11/14 21:15
Weekly Report: what happened at AKTX last week (1104-1108)?
Weekly Report · 11/11 10:00
Akari Therapeutics Merges with Peak Bio for Growth
TipRanks · 11/08 13:32
Akari Therapeutics announce shareholder approval connected with Peak Bio merger
TipRanks · 11/08 13:11
Akari Therapeutics Gains Shareholder Approval For Merger With Peak Bio
Benzinga · 11/08 13:09
AKARI THERAPEUTICS ANNOUNCES SHAREHOLDER APPROVAL IN CONNECTION WITH PEAK BIO, INC. MERGER
Reuters · 11/08 13:00
AKARI THERAPEUTICS PLC - MERGER TO RESULT IN 50% EQUITY OWNERSHIP FOR AKARI AND PEAK BIO SHAREHOLDERS
Reuters · 11/08 13:00
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
Barchart · 11/08 07:00
Weekly Report: what happened at AKTX last week (1028-1101)?
Weekly Report · 11/04 10:00
Weekly Report: what happened at AKTX last week (1021-1025)?
Weekly Report · 10/28 09:56
Weekly Report: what happened at AKTX last week (1014-1018)?
Weekly Report · 10/21 09:55
Akari Therapeutics announces effectiveness of Form S-4 related to merger
TipRanks · 10/15 12:15
AKARI THERAPEUTICS ANNOUNCES EFFECTIVENESS OF FORM S-4 AND GENERAL MEETING DATE OF NOVEMBER 7, 2024 RELATED TO PEAK BIO MERGER
Reuters · 10/15 12:00
Weekly Report: what happened at AKTX last week (1007-1011)?
Weekly Report · 10/14 10:06
More
Webull provides a variety of real-time AKTX stock news. You can receive the latest news about Akari Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. The Company is engaged in the development of antibody drug conjugates (ADCs) and advanced therapies for autoimmune and inflammatory diseases, including geographic atrophy (GA). Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. The Company is conducting pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). It is conducting a phase III clinical trial in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). The Company's pipeline also includes the PH-1 ADC Platform for oncology, PHP-303 program for genetic disease, liver disease and inflammation, specifically for Alpha-1 antitrypsin deficiency (AATD) and acute respiratory distress syndrome (ARDS), including COVID-19.